

and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19 0036.

### ***Amendments to the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

1-18. (cancelled).

19. (original) A method of screening for agonists or antagonists of PTH receptor activity comprising:

- (a) contacting a test compound to cells expressing a PTH receptor; and
- (b) measuring the biological response of said cells.

20. (new) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

(a) contacting cells with a test compound wherein said cells express a rDNA polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(i) the amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2;

(ii) the amino acid sequence from about position 2 to about position 435 in SEQ ID NO:2;

(iii) the amino acid sequence from about position 23 to about position 435 in SEQ ID NO:2;

(iv) the amino acid sequence of the rδNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136; and

(v) the amino acid sequence of the mature rδNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136;

and

(b) measuring the biological response of said cells.

21. (new) The method of claim 20, wherein said biological response is cAMP accumulation.

22. (new) The method of claim 20, wherein said agonist is a peptide.

23. (new) The method of claim 20, wherein said antagonist is a peptide.

24. (new) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

(a) contacting cells with a test compound wherein said cells express a rδNt polypeptide, wherein said cells comprise a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(i) a nucleotide sequence encoding the amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2;

(ii) a nucleotide sequence encoding the amino acid sequence from about position 2 to about position 435 in SEQ ID NO:2;

(iii) a nucleotide sequence encoding the amino acid sequence from about position 23 to about position 435 in SEQ ID NO:2;

(iv) a nucleotide sequence encoding the rδNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136; and

(v) a nucleotide sequence encoding the mature rδNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136;

and

(b) measuring the biological response of said cells.

25. (new) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

(a) contacting cells with a test compound wherein said cells express a rδNt polypeptide having an amino acid sequence selected from the group consisting of:

(i) the amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2;

(ii) the amino acid sequence from about position 2 to about position 435 in SEQ ID NO:2;

(iii) the amino acid sequence from about position 23 to about position 435 in SEQ ID NO:2;

(iv) the amino acid sequence of the rδNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136; and

(v) the amino acid sequence of the mature rδNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136;

and

(b) measuring the biological response of said cells.

26. (new) A method of screening for an agonist or an antagonist of PTH receptor activity comprising:

(a) contacting cells with a test compound wherein said cells express a rδNt polypeptide, wherein said cells comprise a polynucleotide having a nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence encoding the amino acid sequence from about position 1 to about position 435 in SEQ ID NO:2;

(ii) a nucleotide sequence encoding the amino acid sequence from about position 2 to about position 435 in SEQ ID NO:2;

(iii) a nucleotide sequence encoding the amino acid sequence from about position 23 to about position 435 in SEQ ID NO:2;

(iv) a nucleotide sequence encoding the rδNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136; and

(v) a nucleotide sequence encoding of the mature rδNt polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. PTA-1136;

and

(b) measuring the biological response of said cells.